• Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
    • Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.
    • Clin Cancer Res. 2018 Dec 15;24(24):6277-6287. doi: 10.1158/1078-0432.CCR-18-0063. Epub 2018 Aug 23.
    • Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report.
    • Lin Z, Liu J, Peng L, Zhang D, Jin M, Wang J, Xue J, Liu H, Zhang T.
    • BMC Cancer. 2018 Dec 14;18(1):1253. doi: 10.1186/s12885-018-5182-z.
    • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    • Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.
    • EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.
    • Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
    • Wang Z, Zhang J, Zhang Y, Deng Q, Liang H.
    • Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
    • Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
    • Lan B, Ma F, Chen S, Wang W, Li Q, Fan Y, Luo Y, Cai R, Wang J, Yuan P, Zhang P, Li Q, Xu B.
    • Int J Cancer. 2018 Nov 15;143(10):2499-2504. doi: 10.1002/ijc.31639. Epub 2018 Sep 19.
    • Evaluating Clinical Genome Sequence Analysis by Watson for Genomics.
    • Itahashi K, Kondo S, Kubo T, Fujiwara Y, Kato M, Ichikawa H, Koyama T, Tokumasu R, Xu J, Huettner CS, Michelini VV, Parida L, Kohno T, Yamamoto N.
    • Front Med (Lausanne). 2018 Nov 9;5:305. doi: 10.3389/fmed.2018.00305. eCollection 2018.
    • Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.
    • Pearre DC, Tewari KS.
    • Ther Clin Risk Manag. 2018 Nov 2;14:2189-2201. doi: 10.2147/TCRM.S149248. eCollection 2018.
    • Pricey Precision Medicine Often Financially Toxic For Cancer Patients.
    • Szabo L.
    • Kaiser Health News. 2018 Nov 1.

    Research News: The cost of cancer care and impact of financial hardship on treatment. (FORCE XRAYS)

    • Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations.
    • Sweis RF, Heiss B, Segal J, Ritterhouse L, Kadri S, Churpek JE, Allen K, Conway D, Marinier C, Smith ND, Pitroda SP, Stadler WM.
    • JCO Precis Oncol. 2018 Nov;2:1-7. doi: 10.1200/PO.18.00264.
    • The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
    • Sorscher S.
    • Oncologist. 2018 Nov;23(11):1266-1268. doi: 10.1634/theoncologist.2017-0681. Epub 2018 Jun 4.
    • Case report
    • Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
    • Ungerleider NA, Rao SG, Shahbandi A, Yee D, Niu T, Frey WD, Jackson JG.
    • Breast Cancer Res. 2018 Oct 1;20(1):115. doi: 10.1186/s13058-018-1044-5.
    • BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.
    • Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, Okido M, Kuroki S, Oda Y, Nakamura M.
    • Clin Breast Cancer. 2018 Oct;18(5):e1217-e1227. doi: 10.1016/j.clbc.2018.05.008. Epub 2018 Jun 2.
    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
    • Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.
    • Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.
    • A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    • Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.
    • Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.
    • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
    • Li G, Guo X, Chen M, Tang L, Jiang H, Day JX, Xie Y, Peng L, Xu X, Li J, Wang S, Xiao Z, Dai L, Wang J.
    • PLoS One. 2018 Sep 13;13(9):e0203495. doi: 10.1371/journal.pone.0203495. eCollection 2018.
    • Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    • Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z.
    • Ann Oncol. 2018 Sep 1;29(9):1948-1954. doi: 10.1093/annonc/mdy216.
    • BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    • Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.
    • Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.
    • Inherited gynaecological cancers.
    • George A.
    • Curr Opin Oncol. 2018 Sep;30(5):317-322. doi: 10.1097/CCO.0000000000000465.
    • Review
    • Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    • da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE.
    • Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
    • Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents.
    • Ingham MA, McGuinness JE, Kalinsky K, Schwartz GK.
    • JCO Precis Oncol. 2018 Nov [2018 Aug 18];2:1-6. doi: 10.1200/PO.18.00131.
    • Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
    • Murciano-Goroff YR, McCarthy AM, Bristol MN, Groeneveld P, Domchek SM, Motanya UN, Armstrong K.
    • Breast Cancer Res Treat. 2018 Aug;171(1):173-180. doi: 10.1007/s10549-018-4810-2. Epub 2018 May 8.
    • FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
    • Wilkins A, Chauhan R, Rust A, Pearson A, Daley F, Manodoro F, Fenwick K, Bliss J, Yarnold J, Somaiah N.
    • Breast Cancer Res Treat. 2018 Aug;170(3):573-581. doi: 10.1007/s10549-018-4798-7. Epub 2018 Feb 22.
    • Expression signature of ten genes predicts the survival of patients with estrogen receptor positive-breast cancer that were treated with tamoxifen.
    • Huang H, Chen Q, Sun W, Lu M, Yu Y, Zheng Z, Li P.
    • Oncol Lett. 2018 Jul;16(1):573-579. doi: 10.3892/ol.2018.8663. Epub 2018 May 8.
    • Association of Germline PALB2 Mutation and Response to Platinum-Based Chemotherapy in Metastatic Breast Cancer: A Case Series.
    • Isaac D, Karapetyan L, Tamkus D.
    • JCO Precis Oncol. 2018 Nov [2018 Jun 26];2:1-5. doi: 10.1200/PO.17.00258.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di L
    • Clin Cancer Res. 2018 Jun 12. doi: 10.1158/1078-0432.CCR-17-3862. [Epub ahead of print]
    • MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
    • Xie B, Yuan Z, Yang Y, Sun Z, Zhou S, Fang X.
    • Breast Cancer Res Treat. 2018 Jun;169(3):625-632. doi: 10.1007/s10549-018-4708-z. Epub 2018 Feb 10.
    • Database report
    • A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow.
    • Walter VP, Taran FA, Wallwiener M, Walter C, Grischke EM, Wallwiener D, Brucker SY, Hartkopf AD.
    • Breast Cancer Res Treat. 2018 Jun;169(2):305-309. doi: 10.1007/s10549-018-4679-0. Epub 2018 Jan 27.
    • Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.
    • Eterovic AK, Maher OM, Chandra J, Chen K, Huse J, Zaky W.
    • J Natl Compr Canc Netw. 2018 Jun;16(6):683-691. doi: 10.6004/jnccn.2018.7009.
    • Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
    • Li S, Wei Y.
    • Oncol Lett. 2018 Jun;15(6):9572-9576. doi: 10.3892/ol.2018.8482. Epub 2018 Apr 13.
    • Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.
    • Losi L, Fonda S, Saponaro S, Chelbi ST, Lancellotti C, Gozzi G, Alberti L, Fabbiani L, Botticelli L, Benhattar J.
    • Int J Mol Sci. 2018 May 24;19(6). pii: E1559. doi: 10.3390/ijms19061559.
    • Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
    • Cheng H, Powers J, Schaffer K, Sartor O.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):372-381. doi: 10.1200/EDBK_205441.
    • A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
    • Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL.
    • J Clin Invest. 2018 May 1;128(5):2116-2126. doi: 10.1172/JCI97992. Epub 2018 Apr 16.

    Identifier: NCT02637934: Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT. (ClinicalTrials.gov)

    Commentary:

    The evolving landscape of predictive biomarkers of response to PARP inhibitors.

    • Hypermethylation of BRCA1 Gene in Meningioma in Elderly Males.
    • Lombardi IAS, Faria MHG, Rabenhorst SHB, Zanini MA, DE Moura Campos Pardini MI, Grotto RMT, Ferrasi AC.
    • Anticancer Res. 2018 May;38(5):2819-2822.
    • Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
    • Rechsteiner M, Dedes K, Fink D, Pestalozzi B, Sobottka B, Moch H, Wild P, Varga Z.
    • J Cancer Res Clin Oncol. 2018 May;144(5):865-874. doi: 10.1007/s00432-018-2609-5. Epub 2018 Feb 17.
    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    • Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder S, Bliss JM.v
    • Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.
    • Role of tumor microenvironment in ovarian cancer pathobiology.
    • Ghoneum A, Afify H, Salih Z, Kelly M, Said N.
    • Oncotarget. 2018 Apr 27;9(32):22832-22849. doi: 10.18632/oncotarget.25126. eCollection 2018 Apr 27.
    • Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    • Chen J, Wu X, Christos PJ, Formenti S, Nagar H.
    • Breast Cancer Res. 2018 Apr 16;20(1):26. doi: 10.1186/s13058-018-0957-3.
    • Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
    • Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP.
    • J Clin Oncol. 2018 Apr 16:JCO2017765941. doi: 10.1200/JCO.2017.76.5941. [Epub ahead of print]
    • Review
    • Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus.
    • Capoluongo E, Scambia G, Nabholtz JM.
    • Oncotarget. 2018 Apr 13;9(28):19463-19468. doi: 10.18632/oncotarget.24728. eCollection 2018 Apr 13.
    • [Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    • Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
    • Rev Esp Patol. 2018 Apr - Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17.
    • Consensus statement, Review, [Article in Spanish]
    • An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
    • Győrffy B, Pongor L, Bottai G, Li X, Budczies J, Szabó A, Hatzis C, Pusztai L, Santarpia L.
    • Br J Cancer. 2018 Apr;118(8):1107-1114. doi: 10.1038/s41416-018-0030-0. Epub 2018 Mar 21.
    • The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
    • El Ansari R, Craze ML, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.
    • Br J Cancer. 2018 Apr;118(8):1115-1122. doi: 10.1038/s41416-018-0038-5. Epub 2018 Mar 16.
    • Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
    • Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.
    • Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24.

    Research news:

    Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

    • BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
    • Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.
    • Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.
    • DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
    • Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.
    • Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6.
    • Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    • Xiao X, Dong D, He W, Song L, Wang O, Yue J, Xie L.
    • Gynecol Oncol. 2018 Apr;149(1):146-154. doi: 10.1016/j.ygyno.2018.02.009. Epub 2018 Mar 1.
    • Multigene Signature Panels and Breast Cancer Therapy: Patterns of Use and Impact on Clinical Decision Making.
    • Bhutiani N, Egger ME, Ajkay N, Scoggins CR, Martin RC 2nd, McMasters KM.
    • J Am Coll Surg. 2018 Apr;226(4):406-412.e1. doi: 10.1016/j.jamcollsurg.2017.12.043. Epub 2018 Jan 31.

    Commentary: Discussion (Journal of the American College of Surgeons)

    • Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    • Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF.
    • Ann Oncol. 2018 Mar 1;29(3):654-660. doi: 10.1093/annonc/mdx821.
    • ABC4 Consensus: Assessment by a German Group of Experts.
    • Harbeck N, Lüftner D, Marschner N, Untch M, Augustin D, Briest S, Ettl J, Haidinger R, Müller L, Müller V, Ruckhäberle E, Wuerstlein R, Thomssen C.
    • Breast Care (Basel). 2018 Mar;13(1):48-58. doi: 10.1159/000486722. Epub 2018 Feb 15.
    • An evaluation of the challenges to developing tumour BRCA1 and BRCA2 testing methodologies for clinical practice.
    • Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, Röthlisberger B, Ludin K, Merkelbach-Bruse S, Heydt C, Ligtenberg MJL, Mensenkamp AR, Castro DG, Jones T, Vivancos A, Kondrashova O, Pauwels P, Weyn C, Hahnen E, Hauke J, Soong R, Lai Z, Dougherty B, Carr TH, Johnson J, Mills J, Barrett JC.
    • Hum Mutat. 2018 Mar;39(3):394-405. doi: 10.1002/humu.23375. Epub 2017 Dec 28.
    • BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism.
    • Vázquez-Arreguín K, Maddox J, Kang J, Park D, Cano RR, Factor RE, Ludwig T, Tantin D.
    • Mol Cancer Res. 2018 Mar;16(3):439-452. doi: 10.1158/1541-7786.MCR-17-0364. Epub 2018 Jan 12.
    • Spotlight on the utility of the Oncotype DX® breast cancer assay.
    • Siow ZR, De Boer RH, Lindeman GJ, Mann GB.
    • Int J Womens Health. 2018 Feb 21;10:89-100. doi: 10.2147/IJWH.S124520. eCollection 2018.
    • Cost Effectiveness of Gene Expression Profile Testing in Community Practice.
    • Chandler Y, Schechter CB, Jayasekera J, Near A, O'Neill SC, Isaacs C, Phelps CE, Ray GT, Lieu TA, Ramsey S, Mandelblatt JS.
    • J Clin Oncol. 2018 Feb 20;36(6):554-562. doi: 10.1200/JCO.2017.74.5034. Epub 2018 Jan 8.

    Press: Oncotype DX Less Cost-effective in 'Real-World' Settings. (Medscape)

    • NCCN Updated Prostate Cancer Guidelines Include New Genetic Testing Information.
    • [No author given]
    • Precision Oncology News. Diagnostics. 2018 Feb 20.
    • Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    • Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.
    • Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.
    • BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    • Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.
    • Breast Cancer Res Treat. 2018 Feb;167(3):803-814. doi: 10.1007/s10549-017-4552-6. Epub 2017 Nov 7.
    • Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).
    • Bartosch C, Clarke B, Bosse T.
    • Pathology. 2018 Feb;50(2):222-237. doi: 10.1016/j.pathol.2017.10.010. Epub 2017 Dec 26.
    • Review
    • A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow.
    • Walter VP, Taran FA, Wallwiener M, Walter C, Grischke EM, Wallwiener D, Brucker SY, Hartkopf AD.
    • Breast Cancer Res Treat. 2018 Jan 27. doi: 10.1007/s10549-018-4679-0. [Epub ahead of print]
    • Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
    • Mittmann N, Earle CC, Cheng SY, Julian JA, Rahman F, Seung SJ, Levine MN.
    • J Clin Oncol. 2018 Jan 20;36(3):238-243. doi: 10.1200/JCO.2017.74.2577. Epub 2017 Dec 1.
    • Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
    • Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H.
    • JAMA Oncol. 2018 Jan 11;4(1):e173470. doi: 10.1001/jamaoncol.2017.3470. Epub 2018 Jan 11.

    Press: 70-gene Test May Help Guide Treatment for Some Women With Early Breast Cancer. (Medscape)

    • Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
    • Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litière S, Cardoso F; MINDACT investigators.
    • Breast Cancer Res Treat. 2018 Jan;167(1):123-131. doi: 10.1007/s10549-017-4509-9. Epub 2017 Sep 19.
    • Mutation Screening of 10 Cancer Susceptibility Genes in Unselected Breast Cancer Patients.
    • Xie Y, Guoli L, Chen M, Guo X, Tang L, Luo X, Wang S, Yi W, Dai L, Wang J.
    • Clin Genet. 2018 Jan;93(1):41-51. doi: 10.1111/cge.13063. Epub 2017 Sep 25.
    • BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes.
    • Gupta I, Ouhtit A, Al-Ajmi A, Rizvi SGA, Al-Riyami H, Al-Riyami M, Tamimi Y.
    • Endocr Connect. 2018 Jan;7(1):65-77. doi: 10.1530/EC-17-0173. Epub 2017 Nov 14.
    • BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
    • Wang GH, Zhao CM, Huang Y, Wang W, Zhang S, Wang X.
    • Hum Pathol. 2018 Jan;71:135-144. doi: 10.1016/j.humpath.2017.10.032. Epub 2017 Nov 8.
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
    • Danzinger S, Tan YY, Rudas M, Kastner MT, Weingartshofer S, Muhr D, Singer CF; kConFab Investigators.
    • Cancer Invest. 2018;36(7):378-388. doi: 10.1080/07357907.2018.1499934. Epub 2018 Aug 24.
    • BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
    • Kumar M, Sahu RK, Goyal A, Sharma S, Kaur N, Mehrotra R, Singh UR, Hedau S.
    • Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3293-3299.
    • [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    • Li MJ, Li HR, Cheng X, Bi R, Tu XY, Liu F, Chen LH.
    • Zhonghua Fu Chan Ke Za Zhi. 2017 Dec 25;52(12):835-843. doi: 10.3760/cma.j.issn.0529-567x.2017.12.008.
    • [Article in Chinese]
    • Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    • Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.
    • Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.
    • High expression of PALB2 predicts poor prognosis in patients with advanced breast cancer.
    • Li J, Li M, Chen P, Ba Q.
    • FEBS Open Bio. 2017 Dec 13;8(1):56-63. doi: 10.1002/2211-5463.12356. eCollection 2018 Jan.
    • Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.
    • Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, Mills GB, Laird PW, Shriver CD, Perou CM, Olopade OI.
    • JAMA Oncol. 2017 Dec 1;3(12):1654-1662. doi: 10.1001/jamaoncol.2017.0595.

    Letter, Comment:

    Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening.

    Letter, Reply:

    Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply.

    • Network Meta-Analysis on the Effects of DNA Damage Response-Related Gene Mutations on Overall Survival of Breast Cancer Based on TCGA Database.
    • Liu C, Chang H, Li XH, Qi YF, Wang JO, Zhang Y, Yang XH.
    • J Cell Biochem. 2017 Dec;118(12):4728-4734. doi: 10.1002/jcb.26140. Epub 2017 Jun 22.
    • Meta-Analysis
    • Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.
    • Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B.
    • Oncotarget. 2017 Sep 8;8(60):101325-101332. doi: 10.18632/oncotarget.20722. eCollection 2017 Nov 24.
    • The roles of pathology in targeted therapy of women with gynecologic cancers.
    • Murali R, Grisham RN, Soslow RA.
    • Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530-5. doi: 10.1016/j.ygyno.2017.11.020. [Epub ahead of print]
    • Review
    • Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care.
    • Walsh MF, Kennedy J, Harlan M, Kentsis A, Shukla N, Musinsky J, Roberts S, Kung AL, Robson M, Kushner BH, Meyers P, Offit K.
    • Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6). pii: a001925. doi: 10.1101/mcs.a001925. Print 2017 Nov.
    • Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition.
    • Bhangoo MS, Costantini C, Clifford BT, Chung JH, Schrock AB, Ali SM, Klempner SJ.
    • JCO Precis Oncol. 2017 Nov;1:1-7. doi: 10.1200/PO.17.00043.
    • Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
    • Wang Y, Ung MH, Cantor S, Cheng C.
    • Sci Rep. 2017 Nov 16;7(1):15742. doi: 10.1038/s41598-017-16138-2.
    • Who are the long-term survivors of high grade serous ovarian cancer?
    • Hoppenot C, Eckert MA, Tienda SM, Lengyel E.
    • Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31454-3. doi: 10.1016/j.ygyno.2017.10.032. [Epub ahead of print]
    • Review
    • Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    • Lanz HL, Saleh A, Kramer B, Cairns J, Ng CP, Yu J, Trietsch SJ, Hankemeier T, Joore J, Vulto P, Weinshilboum R, Wang L.
    • BMC Cancer. 2017 Nov 2;17(1):709. doi: 10.1186/s12885-017-3709-3.
    • Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
    • Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS.
    • JAMA Oncol. 2017 Nov 1;3(11):1503-1510. doi: 10.1001/jamaoncol.2017.1261.

    Press: Molecular Test May Help Identify Ultralow-Risk Breast Cancer Patients. (OncoTherapy Network)

    • Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
    • Kawahara N, Ogawa K, Nagayasu M, Kimura M, Sasaki Y, Kobayashi H.
    • Biomed Rep. 2017 Nov;7(5):391-399. doi: 10.3892/br.2017.990. Epub 2017 Sep 27.
    • Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
    • van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS.
    • Breast Cancer Res Treat. 2017 Nov;166(2):593-601. doi: 10.1007/s10549-017-4428-9. Epub 2017 Aug 4.
    • 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
    • Turashvili G, Chou JF, Brogi E, Morrow M, Dickler M, Norton L, Hudis C, Wen HY.
    • Breast Cancer Res Treat. 2017 Nov;166(1):69-76. doi: 10.1007/s10549-017-4381-7. Epub 2017 Jul 12.
    • A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
    • Biermann J, Nemes S, Parris TZ, Engqvist H, Rönnerman EW, Forssell-Aronsson E, Steineck G, Karlsson P, Helou K.
    • Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1619-1628. doi: 10.1158/1055-9965.EPI-17-0606. Epub 2017 Sep 6.
    • Combining Enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.
    • Thompson TC, Li L, Broom BM.
    • Oncotarget. 2017 Oct 25. doi: 10.18632/oncotarget.22074. [Epub ahead of print]
    • Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
    • Peethambaram PP, Hoskin TL, Day CN, Goetz MP, Habermann EB, Boughey JC.
    • NPJ Breast Cancer. 2017 Oct 19;3:41. doi: 10.1038/s41523-017-0044-4. eCollection 2017.
    • Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
    • Thomas SN, Chen L, Liu Y, Hoti N, Zhang H.
    • J Proteome Res. 2017 Oct 6;16(10):3704-3710. doi: 10.1021/acs.jproteome.7b00405. Epub 2017 Sep 14.
    • Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas.
    • Madubata CJ, Roshan-Ghias A, Chu T, Resnick S, Zhao J, Arnes L, Wang J, Rabadan R.
    • NPJ Genom Med. 2017 Oct 3;2:29. doi: 10.1038/s41525-017-0032-5. eCollection 2017.
    • [A bioinformatic pipeline for NGS data analysis and mutation calling in human solid tumors].
    • Tsukanov KY, Krasnenko AY, Plakhina DA, Korostin DO, Churov AV, Druzhilovskaya OS, Rebrikov DV, Ilinsky VV.
    • Biomed Khim. 2017 Oct;63(5):413-417. doi: 10.18097/PBMC20176305413.
    • [Article in Russian]
    • Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients.
    • Jeong HM, Kim RN, Kwon MJ, Oh E, Han J, Lee SK, Choi JS, Park S, Nam SJ, Gong GY, Nam JW, Choi DH, Lee H, Nam BH, Choi YL, Shin YK.
    • Oncotarget. 2017 Jun 27;8(37):61538-61550. doi: 10.18632/oncotarget.18618. eCollection 2017 Sep 22.
    • Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    • Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.
    • JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137.

    Editorial:

    The Potential and Challenges of Expanded Germline Testing in Clinical Oncology.

    Press: Study Shows More Cancer Mutations Detected by Universal Sequencing. (Clinical Omics)

    Press: Expanding Germline Analyses to Prevent and Treat Cancers. (Medscape)

    • Current Challenges Associated With Next-Generation Sequencing of Breast Cancer.
    • Sorscher S.
    • JAMA Oncol. 2017 Sep 1;3(9):1283-1284. doi: 10.1001/jamaoncol.2017.0659.
    • Letter, Comment

    Review:

    The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.

    Letter, Reply:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply.

    • Quantitation of Targetable Somatic Mutations among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
    • Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK.
    • Pharmacotherapy. 2017 Sep;37(9):1043-1051. doi: 10.1002/phar.1917. Epub 2017 Apr 2.
    • DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    • Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
    • NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.
    • Implementation and utilization of the molecular tumor board to guide precision medicine.
    • Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES.
    • Oncotarget. 2017 Jun 14;8(34):57845-57854. doi: 10.18632/oncotarget.18471. eCollection 2017 Aug 22.
    • Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.
    • Kuijer A, Straver M, den Dekker B, van Bommel ACM, Elias SG, Smorenburg CH, Wesseling J, Linn SC, Rutgers EJT, Siesling S, van Dalen T.
    • J Clin Oncol. 2017 Aug 20;35(24):2814-2819. doi: 10.1200/JCO.2016.70.3959. Epub 2017 Mar 13.
    • Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
    • Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V.
    • J Clin Oncol. 2017 Aug 20;35(24):2838-2847. doi: 10.1200/JCO.2017.74.0472. Epub 2017 Jul 10.

    Summary:

    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary.

    Press: ASCO Adds MammaPrint to Breast Cancer Guideline. (MEDSCAPE)

    • The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
    • Turashvili G, Brogi E, Morrow M, Hudis C, Dickler M, Norton L, Wen HY.
    • Breast Cancer Res Treat. 2017 Aug;165(1):65-76. doi: 10.1007/s10549-017-4326-1. Epub 2017 Jun 3.
    • Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    • Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkjær L, Tischkowitz M, Haile RW, Shen R, Malone KE, Woods M, Liang X, Morrow M, Bernstein JL; WECARE Study Collaborative Group.
    • Breast Cancer Res. 2017 Jul 19;19(1):83. doi: 10.1186/s13058-017-0874-x.
    • My Tumor Carries A BRCA Mutation. Does This Mean I’m A BRCA Carrier?
    • [No author given]
    • My Gene Counsel. 2017 Jul 7.
    • Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
    • Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.
    • Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.
    • Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    • Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC.
    • Oncotarget. 2017 Jul 4;8(27):43653-43661. doi: 10.18632/oncotarget.17613.

    Research news:

    Olaparib and somatic BRCA mutations.

    • Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    • Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG Jr, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D.
    • Cancer. 2017 Jul 1;123(13):2422-2431. doi: 10.1002/cncr.30618. Epub 2017 Feb 15.
    • Magee equations and oncotype DX®-a perspective.
    • Bhargava R, Dabbs DJ.
    • Breast Cancer Res Treat. 2017 Jul;164(1):245-246. doi: 10.1007/s10549-017-4235-3. Epub 2017 Apr 9.
    • Letter
    • The value of algorithms predicting the Oncotype DX recurrence score should not be underestimated!
    • Turner B, Tang P, Hicks D.
    • Breast Cancer Res Treat. 2017 Jul;164(1):249-250. doi: 10.1007/s10549-017-4236-2. Epub 2017 Apr 13.
    • Letter
    • Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    • Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.
    • J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.
    • Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling.
    • Hamilton JG, Shuk E, Genoff MC, Rodríguez VM, Hay JL, Offit K, Robson ME.
    • J Oncol Pract. 2017 Jul;13(7):e590-e601. doi: 10.1200/JOP.2016.020057. Epub 2017 Jun 19.

    Medscape-style free full text: Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. (Medscape)

    • Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
    • Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, Platanias LC, Gradishar W, Giles FJ, Cristofanilli M.
    • Mol Cancer Ther. 2017 Jul;16(7):1412-1420. doi: 10.1158/1535-7163.MCT-17-0061. Epub 2017 Apr 26.
    • Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
    • Partridge AH, Sepucha K, O'Neill A, Miller KD, Baker E, Dang CT, Northfelt DW, Sledge GW, Schneider BP.
    • Breast Cancer Res Treat. 2017 Jun 23. doi: 10.1007/s10549-017-4338-x. [Epub ahead of print]
    • BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.
    • Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS.
    • Oncotarget. 2017 Jun 20;8(25):39945-39962. doi: 10.18632/oncotarget.18098.

    News:

    New perspectives for colorectal cancer.

    • Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes.
    • Prabhakaran S, Rizk VT, Ma Z, Cheng CH, Berglund AE, Coppola D, Khalil F, Mulé JJ, Soliman HH.
    • Breast Cancer Res. 2017 Jun 19;19(1):71. doi: 10.1186/s13058-017-0864-z.
    • BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.
    • Papadakis ES, Reeves T, Robson NH, Maishman T, Packham G, Cutress RI.
    • Br J Cancer. 2017 Jun 6;116(12):1585-1594. doi: 10.1038/bjc.2017.130. Epub 2017 May 16.

    Letter, Comment

    Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'.

    Letter, Reply:

    Reply to 'Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses''.

    • DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
    • De Gregoriis G, Ramos JA, Fernandes PV, Vignal GM, Brianese RC, Carraro DM, Monteiro AN, Struchiner C, Suarez-Kurtz G, Vianna-Jorge R, de Carvalho MA.
    • Cancer Biol Ther. 2017 Jun 3;18(6):439-449. doi: 10.1080/15384047.2017.1323590. Epub 2017 May 5.
    • Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    • Yanagawa T, Kagara N, Miyake T, Tanei T, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S.
    • Breast Cancer Res Treat. 2017 Jun;163(2):231-240. doi: 10.1007/s10549-017-4190-z. Epub 2017 Mar 10.
    • Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    • Roberts MC, Miller DP, Shak S, Petkov VI.
    • Breast Cancer Res Treat. 2017 Jun;163(2):303-310. doi: 10.1007/s10549-017-4162-3. Epub 2017 Feb 27.
    • Breast cancer and genomic testing.
    • Liedtke C, Kolberg HC.
    • Br J Surg. 2017 Jun;104(7):799-801. doi: 10.1002/bjs.10513. Epub 2017 Mar 16.
    • Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.
    • Kawaguchi T, Foster BA, Young J, Takabe K.
    • J Mammary Gland Biol Neoplasia. 2017 Jun;22(2):131-139. doi: 10.1007/s10911-017-9378-7. Epub 2017 Apr 27.
    • Review
    • Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    • Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN.
    • J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.
    • BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    • Vos S, Moelans CB, van Diest PJ.
    • Breast Cancer Res. 2017 May 31;19(1):64. doi: 10.1186/s13058-017-0856-z.
    • An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
    • Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, Schraml P, Symmans F, Stoehr R, Teng X, Turzynski A, von Wasielewski R, Gürtler C, Laible M, Schlombs K, Joensuu H, Keller T, Sinn P, Sahin U, Bartlett J, Viale G.
    • Breast Cancer Res. 2017 May 11;19(1):55. doi: 10.1186/s13058-017-0848-z.
    • Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.
    • Trifiletti DM, Sturz VN, Showalter TN, Lobo JM.
    • PLoS One. 2017 May 9;12(5):e0176388. doi: 10.1371/journal.pone.0176388. eCollection 2017.
    • Prognostic value of histone chaperone FACT subunits expression in breast cancer.
    • Attwood K, Fleyshman D, Prendergast L, Paszkiewicz G, Omilian AR, Bshara W, Gurova K.
    • Breast Cancer (Dove Med Press). 2017 May 3;9:301-311. doi: 10.2147/BCTT.S126390. eCollection 2017.
    • Genomic Testing and Precision Medicine in Cancer Care.
    • West HJ, Miller G.
    • Medscape. News & Perspective. 2017 May 2.
    • Discussing molecular testing in oncology care: Comparing patient and physician information preferences.
    • Pinheiro APM, Pocock RH, Switchenko JM, Dixon MD, Shaib WL, Ramalingam SS, Pentz RD.
    • Cancer. 2017 May 1;123(9):1610-1616. doi: 10.1002/cncr.30494. Epub 2017 Jan 31.
    • Use of Biomarkers and Multigene Assays in Breast Cancer.
    • Schwartzberg, LS.
    • J Natl Compr Canc Netw. 2017 May 1;15(5 Suppl):676-678.
    • Review
    • Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    • Orucevic A, Bell JL, McNabb AP, Heidel RE.
    • Breast Cancer Res Treat. 2017 May;163(1):51-61. doi: 10.1007/s10549-017-4170-3. Epub 2017 Feb 27.
    • Oncologist and organizational factors associated with variation in breast cancer multigene testing.
    • Lieu TA, Ray GT, Prausnitz SR, Habel LA, Alexeeff S, Li Y, Ramsey SD, Phelps CE, Chawla N, C O'Neill S, Mandelblatt JS.
    • Breast Cancer Res Treat. 2017 May;163(1):167-176. doi: 10.1007/s10549-017-4158-z. Epub 2017 Feb 21.
    • Retrospective review of genomic testing in breast cancer: Does it improve outcome?
    • Gastelum GM, Iqbal C, Hilsenbeck SG, Rimawi MF, Niravath P.
    • Breast Cancer Res Treat. 2017 May;163(1):191-195. doi: 10.1007/s10549-017-4154-3. Epub 2017 Feb 21.
    • Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.
    • Purshouse K, Schuh A, Fairfax BP, Knight S, Antoniou P, Dreau H, Popitsch N, Gatter K, Roberts I, Browning L, Traill Z, Kerr D, Verrill C, Tuthill M, Taylor JC, Protheroe A.
    • Cold Spring Harb Mol Case Stud. 2017 May;3(3):a001362. doi: 10.1101/mcs.a001362.
    • Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
    • Markopoulos C, van de Velde C, Zarca D, Ozmen V, Masetti R.
    • Eur J Surg Oncol. 2017 May;43(5):909-920. doi: 10.1016/j.ejso.2016.08.012. Epub 2016 Aug 31.
    • Review
    • A novel molecular diagnostics platform for somatic and germline precision oncology.
    • Cabanillas R, Diñeiro M, Castillo D, Pruneda PC, Penas C, Cifuentes GA, de Vicente Á, Durán NS, Álvarez R, Ordóñez GR, Cadiñanos J.
    • Mol Genet Genomic Med. 2017 Apr 23;5(4):336-359. doi: 10.1002/mgg3.291. eCollection 2017 Jul.
    • Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
    • Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).
    • BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.
    • Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
    • Green AR, Aleskandarany MA, Ali R, Hodgson EG, Atabani S, De Souza K, Rakha E, Ellis IO, Madhusudan S.
    • Cancer Immunol Res. 2017 Apr;5(4):292-299. doi: 10.1158/2326-6066.CIR-16-0195. Epub 2017 Mar 2.
    • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    • Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.
    • Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.
    • Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.
    • McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY.
    • NPJ Syst Biol Appl. 2017 Mar 6;3:8. doi: 10.1038/s41540-017-0011-6. eCollection 2017.
    • Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
    • Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP.
    • J Natl Compr Canc Netw. 2017 Mar;15(3):346-354.
    • Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    • Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.
    • J Ovarian Res. 2017 Feb 10;10(1):9. doi: 10.1186/s13048-017-0304-9.
    • The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.
    • Niravath P, Cakar B, Ellis M.
    • JAMA Oncol. 2017 Feb 1;3(2):262-268. doi: 10.1001/jamaoncol.2016.2719.
    • Review

    Letter, Comment:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer.

    Letter, Reply:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply.

    • Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
    • Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA.
    • Breast Cancer Res Treat. 2017 Feb;162(1):1-10. doi: 10.1007/s10549-016-4093-4. Epub 2017 Jan 7.
    • Review
    • Molecularly confirmed Li-Fraumeni-like syndrome in a patient with breast cancer and a low pre-test probability for harboring a germline CHEK2 truncation
    • Sorscher S
    • Integr Cancer Sci Ther. 2017 Feb;4(1). doi: 10.15761/ICST.1000224. Epub 2017 Feb 27.
    • 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    • Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N.
    • J Natl Cancer Inst. 2017 Jan 25;109(4). pii: djw259. doi: 10.1093/jnci/djw259. Print 2017 Jan.

    Editorial:

    Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?

    • Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
    • Friese CR, Li Y, Bondarenko I, Hofer TP, Ward KC, Hamilton AS, Deapen D, Kurian AW, Katz SJ.
    • Cancer. 2017 Jan 1;123(1):43-51. doi: 10.1002/cncr.30324. Epub 2016 Oct 24.
    • Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab.
    • Li H, Feng B, Miron A, Chen X, Beesley J, Bimeh E, Barrowdale D, John EM, Daly MB, Andrulis IL, Buys SS, Kraft P; kConFab investigators, Thorne H, Chenevix-Trench G, Southey MC, Antoniou AC, James PA, Terry MB, Phillips KA, Hopper JL, Mitchell G, Goldgar DE.
    • Genet Med. 2017 Jan;19(1):30-35. doi: 10.1038/gim.2016.43. Epub 2016 May 12.
    • Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.
    • Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J.
    • J Hum Genet. 2017 Jan;62(1):15-24. doi: 10.1038/jhg.2016.89. Epub 2016 Jul 21.
    • Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.
    • Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BA, Rakha EA, Nolan CC, Ellis IO, Green AR.
    • Pathol Res Pract. 2017 Jan;213(1):27-33. doi: 10.1016/j.prp.2016.10.005. Epub 2016 Oct 25.
    • Molecular Tests for the Choice of Cancer Therapy.
    • Sokolenko AP, Imyanitov EN.
    • Curr Pharm Des. 2017;23(32):4794-4806. doi: 10.2174/1381612823666170719110125.
    • Review
    • Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
    • Mihalcea CE, Moroşanu AM, Murăraşu D, Puiu L, Cinca SA, Voinea SC, Mirancea N.
    • Rom J Morphol Embryol. 2017;58(2):445-455.
    • Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
    • Shakeri H, Fakhrjou A, Nikanfar A, Mohaddes-Ardebili SM.
    • Clin Lab. 2016 Dec 1;62(12):2333-2337. doi: 10.7754/Clin.Lab.2016.160418.
    • BRCA1 expression in benign and malignant breast lesions.
    • Fernández Á, Reigosa A.
    • Invest Clin. 2016 Dec;57(4):330-51.
    • Aberrant promoter methylation of cancer-related genes in human breast cancer.
    • Wu L, Shen Y, Peng X, Zhang S, Wang M, Xu G, Zheng X, Wang J, Lu C.
    • Oncol Lett. 2016 Dec;12(6):5145-5155. doi: 10.3892/ol.2016.5351. Epub 2016 Nov 4.
    • Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers.
    • Rantalainen M, Klevebring D, Lindberg J, Ivansson E, Rosin G, Kis L, Celebioglu F, Fredriksson I, Czene K, Frisell J, Hartman J, Bergh J, Grönberg H.
    • Sci Rep. 2016 Nov 30;6:38037. doi: 10.1038/srep38037.
    • Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
    • Goetz MP, Ratain M, Ingle JN.
    • J Clin Oncol. 2016 Nov 10;34(32):3944-3945. doi: 10.1200/JCO.2016.68.5214.
    • A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    • Dong F, Davineni PK, Howitt BE, Beck AH.
    • Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1511-1516. Epub 2016 Aug 5.
    • Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers.
    • Dunkel Y, Diao K, Aznar N, Swanson L, Liu L, Zhu W, Mi X, Ghosh P.
    • FASEB J. 2016 Nov;30(11):3702-3713. Epub 2016 Jul 20.
    • [Perspectives of Individualized Treatment by Genome-Wide Analyses in Ovarian Cancer].
    • Matsumura N, Yamaguchi K, Murakami R, Mandai M, Konishi I.
    • Gan To Kagaku Ryoho. 2016 Nov;43(11):1316-1320.
    • [Article in Japanese]
    • Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.
    • Chen S, Cavazza E, Barlier C, Salleron J, Filhine-Tresarrieu P, Gavoilles C, Merlin JL, Harlé A.
    • Oncol Lett. 2016 Nov;12(5):3264-3272. Epub 2016 Sep 2.
    • Genetic Tests That Make a Difference After a Breast Cancer Diagnosis.
    • Marisa C. Weiss
    • U.S. News and World Report. Health Care. Oct. 24, 2016.
    • Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
    • Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D.
    • Clin Cancer Res. 2016 Oct 15;22(20):5043-5048. Epub 2016 Jun 1.
    • Genomic profiling of breast cancer in African-American women using MammaPrint.
    • Nunes RA, Wray L, Mete M, Herbolsheimer P, Smith KL, Bijelic L, Boisvert ME, Swain SM.
    • Breast Cancer Res Treat. 2016 Oct;159(3):481-8. doi: 10.1007/s10549-016-3949-y. Epub 2016 Aug 27.
    • Genomic Disparities in Breast Cancer Among Latinas.
    • Lynce F, Graves KD, Jandorf L, Ricker C, Castro E, Moreno L, Augusto B, Fejerman L, Vadaparampil ST.
    • Cancer Control. 2016 Oct;23(4):359-372.
    • Implementation of the 21-gene recurrence score test in the United States in 2011.
    • Lynch JA, Berse B, Petkov V, Filipski K, Zhou Y, Khoury MJ, Hassett M, Freedman AN.
    • Genet Med. 2016 Oct;18(10):982-90. doi: 10.1038/gim.2015.218. Epub 2016 Feb 11.
    • A cancer patient’s tumor is genetically profiled—how does that info help her treatment?
    • Lisa Rezende, Julie Huynh
    • FORCE. XRAYS. 2016 Sep 20
    • Despite progress, genetic profiling of tumors has a long way to go.
    • Jessica Wapner.
    • Scientific American. 2016 Sep 1.
    • 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
    • Parsons BM, Landercasper J, Smith AL, Go RS, Borgert AJ, Dietrich LL.
    • Breast Cancer Res Treat. 2016 Sep;159(2):315-26. doi: 10.1007/s10549-016-3926-5. Epub 2016 Aug 9.
    • New challenges for BRCA testing: a view from the diagnostic laboratory.
    • Wallace AJ.
    • Eur J Hum Genet. 2016 Sep;24 Suppl 1:S10-8. doi: 10.1038/ejhg.2016.94.
    • Next-Generation Sequencing: Role in Gynecologic Cancers.
    • Evans T, Matulonis U.
    • J Natl Compr Canc Netw. 2016 Sep;14(9):1165-73.
    • Review
    • 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    • Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.
    • N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

    Comment, Editorial

    Increasing Precision in Adjuvant Therapy for Breast Cancer.

    Commentary

    Uncertainty in the Era of Precision Medicine.

    News: Study Of Breast Cancer Treatment Reveals Paradox Of Precision Medicine. (NPR. All Things Considered.)

    Press: Gene Tests Identify Breast Cancer Patients Who Can Skip Chemotherapy, Study Says. (New York Times. Science.)

    News: MammaPrint Finds Breast Cancer Patients Who Can Skip Chemo. (Medscape Oncology)

    • Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    • Seifert BA, O'Daniel JM, Amin K, Marchuk DS, Patel NM, Parker JS, Hoyle AP, Mose LE, Marron A, Hayward MC, Bizon C, Wilhelmsen KC, Evans JP, Earp HS, Sharpless N, Hayes DN, Berg JS.
    • Clin Cancer Res. 2016 Aug 15;22(16):4087-94. doi: 10.1158/1078-0432.CCR-16-0015. Epub 2016 Apr 15.

    Editorial / Commentary

    Toward Concurrent Testing for Somatic and Germline Variants in Cancer Patients.

    • Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
    • Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME.
    • JAMA Oncol. 2016 Aug 11. doi: 10.1001/jamaoncol.2016.1279. [Epub ahead of print]

    Commentary

    ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg".

    • Mammaprint Reveals Who Can Skip Chemotherapy for Breast Cancer.
    • Schmidt C.
    • J Natl Cancer Inst. 2016 Aug 10;108(8). pii: djw197. doi: 10.1093/jnci/djw197. Print 2016 Aug.
    • News
    • BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    • Moschetta M, George A, Kaye SB, Banerjee S.
    • Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31.
    • Molecular Testing in Breast Cancer: A Guide to Current Practices.
    • Hagemann IS.
    • Arch Pathol Lab Med. 2016 Aug;140(8):815-24. doi: 10.5858/arpa.2016-0051-RA.
    • Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    • Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.
    • Genet Med. 2016 Aug;18(8):770-9. doi: 10.1038/gim.2015.173. Epub 2015 Dec 17.
    • West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
    • Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N.
    • J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.
    • Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
    • Wolmark N, Mamounas EP, Baehner FL, Butler SM, Tang G, Jamshidian F, Sing AP, Shak S, Paik S.
    • J Clin Oncol. 2016 Jul 10;34(20):2350-8. doi: 10.1200/JCO.2015.62.6630. Epub 2016 May 23.
    • Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
    • King TA, Lyman JP, Gonen M, Voci A, De Brot M, Boafo C, Sing AP, Hwang ES, Alvarado MD, Liu MC, Boughey JC, McGuire KP, Van Poznak CH, Jacobs LK, Meszoely IM, Krontiras H, Babiera GV, Norton L, Morrow M, Hudis CA.
    • J Clin Oncol. 2016 Jul 10;34(20):2359-65. doi: 10.1200/JCO.2015.63.1960. Epub 2016 Mar 21.
    • Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice.
    • Dong A, Lu Y, Lu B.
    • J Cancer. 2016 Jul 5;7(11):1441-51. doi: 10.7150/jca.15556. eCollection 2016.
    • New genetic test reduces chemotherapy use in patients with early-stage breast cancer
    • Carrie Printz
    • Cancer. 2016 Jul 1;122(13):1964-5. doi: 10.1002/cncr.30125.
    • BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
    • Ishikawa T, Narui K, Tanabe M, Kida K, Oba MS, Yamada A, Ichikawa Y, Endo I.
    • Eur J Surg Oncol. 2016 Jul;42(7):999-1001. doi: 10.1016/j.ejso.2016.02.246. Epub 2016 Mar 2.
    • Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.
    • Kuijer A, van Bommel AC, Drukker CA, van der Heiden-van der Loo M, Smorenburg CH, Westenend PJ, Linn SC, Rutgers EJ, Elias SG, van Dalen T.
    • Genet Med. 2016 Jul;18(7):720-6. doi: 10.1038/gim.2015.152. Epub 2015 Nov 19.
    • Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
    • Chae EY, Moon WK, Kim HH, Kim WH, Cha JH, Shin HJ, Choi WJ, Han W, Noh DY, Lee SB, Ahn SH.
    • PLoS One. 2016 Jun 30;11(6):e0158461. doi: 10.1371/journal.pone.0158461. eCollection 2016.
    • Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples.
    • Waldemarson S, Kurbasic E, Krogh M, Cifani P, Berggård T, Borg Å, James P.
    • Breast Cancer Res. 2016 Jun 29;18(1):69. doi: 10.1186/s13058-016-0732-2.
    • Gene profiling should be offered to some patients with breast cancer, says NICE.
    • Wise J.
    • BMJ. 2016 Jun 16;353:i3391. doi: 10.1136/bmj.i3391.
    • News
    • 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
    • Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P.
    • J Clin Oncol. 2016 Jun 10;34(17):1995-2002. doi: 10.1200/JCO.2015.65.0887. Epub 2016 Mar 21.
    • How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
    • Marshall DA, Deal K, Bombard Y, Leighl N, MacDonald KV, Trudeau M.
    • BMJ Open. 2016 Jun 2;6(6):e010981. doi: 10.1136/bmjopen-2015-010981.
    • Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
    • Orucevic A, Heidel RE, Bell JL.
    • Breast Cancer Res Treat. 2016 Jun;157(3):427-35. doi: 10.1007/s10549-016-3833-9. Epub 2016 May 20.
    • Patient-Centered Communication for Discussing Oncotype DX Testing.
    • Roberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Wheeler SB.
    • Cancer Invest. 2016 May 27;34(5):205-12. doi: 10.3109/07357907.2016.1172637. Epub 2016 Apr 28.

    Comments from NSGC General Discussion Forum

    Subject: Cancer Investigation Journal- Article needed

    • The topography of mutational processes in breast cancer genomes.
    • Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Sale J, Rada C, Stratton MR, Birney E, Nik-Zainal S.
    • Nat Commun. 2016 May 2;7:11383. doi: 10.1038/ncomms11383.
    • Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
    • Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.
    • Nature. 2016 May 2;534(7605):47-54. doi: 10.1038/nature17676.

    News: Breast cancer mutation map could aid personalised treatment (PHG Foundation)

    Press: Scientists say they now have a near-perfect picture of the genetic events that cause breast cancer. (BBC.com)

    Press: Personalized Breast Cancer Treatment Gets Closer to Reality (Time.com)

    • The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    • Anders CK, Abramson V, Tan T, Dent R.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):34-42. doi: 10.1200/EDBK_159135.
    • Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
    • Ju LL, Zhao CY, Ye KF, Yang H, Zhang J.
    • Eur Rev Med Pharmacol Sci. 2016 May;20(10):1993-2003.
    • A 21-Gene Expression Assay in Breast Cancer.
    • Debled M, Tunon de Lara C, MacGrogran G.
    • N Engl J Med. 2016 Apr 7;374(14):1385-6. doi: 10.1056/NEJMc1515988#SA1.

    Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

    Comment / Letter

    A 21-Gene Expression Assay in Breast Cancer.

    Comment / Letter

    A 21-Gene Expression Assay in Breast Cancer.

    • Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
    • Evans CN, Brewer NT, Vadaparampil ST, Boisvert M, Ottaviano Y, Lee MC, Isaacs C, Schwartz MD, O'Neill SC.
    • Breast Cancer Res Treat. 2016 Apr;156(3):549-55. doi: 10.1007/s10549-016-3780-5. Epub 2016 Apr 8.
    • Equivalence of MammaPrint array types in clinical trials and diagnostics.
    • Beumer I, Witteveen A, Delahaye L, Wehkamp D, Snel M, Dreezen C, Zheng J, Floore A, Brink G, Chan B, Linn S, Bernards R, van 't Veer L, Glas A.
    • Breast Cancer Res Treat. 2016 Apr;156(2):279-87. doi: 10.1007/s10549-016-3764-5. Epub 2016 Mar 22.
    • The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
    • Kuchel A, Robinson T, Comins C, Shere M, Varughese M, Sparrow G, Sahu A, Saunders L, Bahl A, Cawthorn SJ, Braybrooke JP.
    • Br J Cancer. 2016 Mar 29;114(7):731-6. doi: 10.1038/bjc.2016.48. Epub 2016 Mar 8.
    • When Gene Tests for Breast Cancer Reveal Grim Data but No Guidance.
    • Gina Kolata.
    • New York Times. Health. 2016 Mar 11.
    • Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.
    • Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, Kurtz RC, Olson SH, Rustgi AK, Schwartz AG, Stoffel E, Syngal S, Zogopoulos G, Ali SZ, Axilbund J, Chaffee KG, Chen YC, Cote ML, Childs EJ, Douville C, Goes FS, Herman JM, Iacobuzio-Donahue C, Kramer M, Makohon-Moore A, McCombie RW, McMahon KW, Niknafs N, Parla J, Pirooznia M, Potash JB, Rhim AD, Smith AL, Wang Y, Wolfgang CL, Wood LD, Zandi PP, Goggins M, Karchin R, Eshleman JR, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH, Klein AP.
    • Cancer Discov. 2016 Feb;6(2):166-75. doi: 10.1158/2159-8290.CD-15-0402. Epub 2015 Dec 9.
    • Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer.
    • Halabi NM, Martinez A, Al-Farsi H, Mery E, Puydenus L, Pujol P, Khalak HG, McLurcan C, Ferron G, Querleu D, Al-Azwani I, Al-Dous E, Mohamoud YA, Malek JA, Rafii A.
    • PLoS Genet. 2016 Jan 6;12(1):e1005755. doi: 10.1371/journal.pgen.1005755. eCollection 2016.
    • The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    • Anders CK, Abramson V, Tan T, Dent R.
    • Am Soc Clin Oncol Educ Book. 2016;35:34-42. doi: 10.14694/EDBK_159135.
    • Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.
    • Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, Paulden M, Kluibenschädl M, Krahn M, Siebert U.
    • Springerplus. 2015 Dec 1;4:752. doi: 10.1186/s40064-015-1440-6. eCollection 2015.
    • A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.
    • Gage MM, Rosman M, Mylander WC, Giblin E, Kim HS, Cope L, Umbricht C, Wolff AC, Tafra L.
    • Clin Breast Cancer. 2015 Dec;15(6):467-72. doi: 10.1016/j.clbc.2015.04.006. Epub 2015 Apr 23.
    • Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression.
    • Saha S, Mandal P, Ganguly S, Jana D, Ayaz A, Banerjee A, Chouhan R, Sarkar DK.
    • Indian J Surg Oncol. 2015 Dec;6(4):378-83. doi: 10.1007/s13193-015-0449-1. Epub 2015 Aug 21.
    • Impact of a Nurse Navigator on Genomic Testing and Timely Treatment Decision Making in Patients With Breast Cancer.
    • McAllister KA, Schmitt ML.
    • Clin J Oncol Nurs. 2015 Oct 1;19(5):510-2. doi: 10.1188/15.CJON.510-512.

    Press: Impact of a Nurse Navigator on Genomic Testing and Timely Treatment Decision Making in Patients With Breast Cancer. (Medscape)

    • Brave-ish New World-What's Needed to Make Precision Oncology a Practical Reality.
    • MacConaill LE, Lindeman NI, Rollins BJ.
    • JAMA Oncol. 2015 Oct 1;1(7):879-880. doi: 10.1001/jamaoncol.2015.1540.
    • Editorial / Commentary
    • Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.
    • Smyth L, Watson G, Walsh EM, Kelly CM, Keane M, Kennedy MJ, Grogan L, Hennessy BT, O'Reilly S, Coate LE, O'Connor M, Quinn C, Verleger K, Schoeman O, O'Reilly S, Walshe JM.
    • Breast Cancer Res Treat. 2015 Oct;153(3):573-82. doi: 10.1007/s10549-015-3555-4. Epub 2015 Sep 12.
    • To (genetic) test or not to test, that is the question.
    • Mushlin AI.
    • J Comp Eff Res. 2015 Sep;4(5):429-31. doi: 10.2217/cer.15.35. Epub 2015 Sep 21.

    Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.

    • Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse.
    • Stearns V, Park BH.
    • JAMA Oncol. 2015 Aug 1;1(5):569-70. doi: 10.1001/jamaoncol.2015.0761.
    • Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.
    • Marrone M, Stewart A, Dotson WD.
    • Genet Med. 2015 Jul 2;17(7):519-532. doi: 10.1038/gim.2014.140. Epub 2014 Dec 4.
    • Review
    • The Challenges of Incorporating Gene Panels Into Clinical Practice.
    • Kate M. O'Rourke.
    • Medscape Oncology. American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. 2015 Jun 22.
    • The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
    • Alvarado M, Carter DL, Guenther JM, Hagans J, Lei RY, Leonard CE, Manders J, Sing AP, Broder MS, Cherepanov D, Chang E, Eagan M, Hsiao W, Schultz MJ.
    • J Surg Oncol. 2015 Jun;111(8):935-40. doi: 10.1002/jso.23933. Epub 2015 May 28.
    • Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
    • Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH.
    • JAMA Oncol. 2015 May;1(2):158-66. doi: 10.1001/jamaoncol.2015.43.

    Comment

    Refining Treatment Decisions in Older Patients With Breast Cancer.

    • NCCN Recommends Only One Genomic Test for Breast Cancer.
    • Nick Mulcahy
    • Medscape Medical News, National Comprehensive Cancer Network (NCCN) 20th Annual Conference. 2015 Mar 12.
    • The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
    • Issa AM, Chaudhari VS, Marchant GE.
    • Expert Rev Mol Diagn. 2015 Feb;15(2):277-86. doi: 10.1586/14737159.2015.983476. Epub 2014 Dec 5.
    • Multigene prognostic tests in breast cancer: past, present, future.
    • Győrffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L.
    • Breast Cancer Res. 2015 Jan 27;17:11. doi: 10.1186/s13058-015-0514-2.
    • Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    • Duffy MJ, Walsh S, McDermott EW, Crown J.
    • Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23.
    • Review

    Comment / Introductory Journal Article

    Preface.

    • The Influence Of Gene Expression Profiling (GEP) On Decisional Conflict In Chemotherapy Treatment Decision-Making For Early-Stage Breast Cancer (BRCA).
    • Marshall D, MacDonald K, Deal K, Trudeau M, Leighl N, Bombard Y.
    • Value Health. 2014 Nov;17(7):A569. doi: 10.1016/j.jval.2014.08.1899. Epub 2014 Oct 26.
    • Conference abstract
    • Genome-Based Risk Prediction for Early Stage Breast Cancer.
    • Adaniel C, Jhaveri K, Heguy A, Esteva FJ.
    • Oncologist. 2014 Oct;19(10):1019-1027. Epub 2014 Sep 3.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Oncologist article request

    • Impact of Oncotype DX Recurrence Score in the Management of Breast Cancer Cases.
    • Nguyen MT, Stessin A, Nagar H, D'Alfonso TM, Chen Z, Cigler T, Hayes MK, Shin SJ.
    • Clin Breast Cancer. 2014 Jun;14(3):182-90. doi: 10.1016/j.clbc.2013.12.002. Epub 2013 Dec 27.
    • Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma.
    • Parris TZ, Kovács A, Aziz L, Hajizadeh S, Nemes S, Semaan M, Forssell-Aronsson E, Karlsson P, Helou K.
    • Int J Cancer. 2014 Apr 1;134(7):1617-29. doi: 10.1002/ijc.28497. Epub 2013 Oct 12.
    • Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer.
    • Mislick K, Schonfeld W, Bodnar C, Tong KB.
    • Clinicoecon Outcomes Res. 2014 Jan 16;6:37-47. doi: 10.2147/CEOR.S53142. eCollection 2014.
    • Molecular testing in breast cancer.
    • Paoletti C, Hayes DF.
    • Annu Rev Med. 2014 Jan 14;65:95-110. doi: 10.1146/annurev-med-070912-143853.
    • Review
    • The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy.
    • Siegelmann-Danieli N, Silverman B, Zick A, Beit-Or A, Katzir I, Porath A.
    • Ecancermedicalscience. 2013 Dec 17;7:380. doi: 10.3332/ecancer.2013.380. eCollection 2013.
    • Evaluation of ultra-deep targeted sequencing for personalized breast cancer care.
    • Harismendy O, Schwab RB, Alakus H, Yost SE, Matsui H, Hasteh F, Wallace AM, Park HL, Madlensky L, Parker B, Carpenter PM, Jepsen K, Anton-Culver H, Frazer KA.
    • Breast Cancer Res. 2013 Dec 10;15(6):R115. doi: 10.1186/bcr3584.
    • Understanding how breast cancer patients use risk information from genomic tests.
    • DeFrank JT, Carey LA, Brewer NT.
    • J Behav Med. 2013 Dec;36(6):567-73. doi: 10.1007/s10865-012-9449-6. Epub 2012 Aug 10.
    • MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
    • Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Wei M.
    • Tumour Biol. 2013 Dec;34(6):3945-58. doi: 10.1007/s13277-013-0983-9. Epub 2013 Jul 17.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
    • Aktas B, Bankfalvi A, Heubner M, Kimmig R, Kasimir-Bauer S.
    • Mol Clin Oncol. 2013 Nov;1(6):1049-1054. Epub 2013 Sep 2.
    • Who Gets Genomic Testing for Breast Cancer Recurrence Risk?
    • Defrank JT, Salz T, Reeder-Hayes K, Brewer NT.
    • Public Health Genomics. [2013 Oct;]16(5):215-222. Epub 2013 Jul 30.
    • BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
    • Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, Kalinski T, Bischoff J.
    • Breast Cancer Res Treat. 2013 Sep;141(2):205-12. doi: 10.1007/s10549-013-2693-9. Epub 2013 Sep 13.
    • Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10).
    • [No author given]
    • NICE. 2013 Sep.
    • Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
    • Spellman E, Sulayman N, Eggly S, Peshkin BN, Isaacs C, Schwartz MD, O'Neill SC.
    • Psychooncology. 2013 Sep;22(9):2110-6. doi: 10.1002/pon.3264. Epub 2013 Feb 28.
    • The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
    • de Boer RH, Baker C, Speakman D, Chao CY, Yoshizawa C, Mann GB.
    • Med J Aust. 2013 Aug 5;199(3):205-8.
    • The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
    • Carlson JJ, Roth JA.
    • Breast Cancer Res Treat. 2013 Aug;141(1):13-22. doi: 10.1007/s10549-013-2666-z. Epub 2013 Aug 24.
    • Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    • Gan A, Green AR, Nolan CC, Martin S, Deen S.
    • Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.
    • Multiplex DNA sensor for BRAF and BRCA detection.
    • Ai X, Ma Q, Su X.
    • Anal Biochem. 2013 Jul 1;438(1):22-8. doi: 10.1016/j.ab.2013.02.029. Epub 2013 Mar 13.
    • Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    • Paulden M, Franek J, Pham B, Bedard PL, Trudeau M, Krahn M.
    • Value Health. 2013 Jul-Aug;16(5):729-39. doi: 10.1016/j.jval.2013.03.1625. Epub 2013 Jul 1.
    • The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
    • Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S, Lieberman N.
    • Breast Cancer Res Treat. 2013 Jul;140(1):83-92. doi: 10.1007/s10549-013-2603-1. Epub 2013 Jun 26.
    • Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    • Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.
    • Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.
    • Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
    • Galic V, Coleman RL, Herzog TJ.
    • Curr Cancer Drug Targets. 2013 Jul;13(6):698-707.
    • Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
    • Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA.
    • J Oncol Pract. 2013 Jul;9(4):182-7. doi: 10.1200/JOP.2012.000638. Epub 2013 Feb 12.
    • Association between genomic recurrence risk and well-being among breast cancer patients.
    • Retèl VP, Groothuis-Oudshoorn CG, Aaronson NK, Brewer NT, Rutgers EJ, van Harten WH.
    • BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295.
    • Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors.
    • Wu YY, Yen MF, Yu CP, Chen HH.
    • Br J Cancer. 2013 Jun 11;108(11):2241-9. doi: 10.1038/bjc.2013.202. Epub 2013 May 14.
    • A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK.
    • Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, Rolles M, Moe M, Khawaja S, Sharaiha Y, Brinkworth E, Whelan S, Jones S, Bennett H, Phillips CJ.
    • Br J Cancer. 2013 Jun 11;108(11):2250-8. doi: 10.1038/bjc.2013.207. Epub 2013 May 21.
    • Identification of miRNA modulators to PARP inhibitor response.
    • Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A.
    • DNA Repair (Amst). 2013 Jun 1;12(6):394-402. doi: 10.1016/j.dnarep.2013.02.003. Epub 2013 Apr 6.
    • Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
    • Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y.
    • Ann Oncol. 2013 Jun;24(6):1498-505. doi: 10.1093/annonc/mdt011. Epub 2013 Feb 13.
    • Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses.
    • Rouzier R, Pronzato P, Chéreau E, Carlson J, Hunt B, Valentine WJ.
    • Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31.
    • BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    • D'Alfonso TM, van Laar RK, Vahdat LT, Hussain W, Flinchum R, Brown N, John LS, Shin SJ.
    • Breast Cancer Res Treat. 2013 Jun;139(3):705-15. doi: 10.1007/s10549-013-2604-0. Epub 2013 Jun 18.
    • Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
    • Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM.
    • Breast Cancer Res Treat. 2013 Jun;139(2):317-27. doi: 10.1007/s10549-013-2558-2. Epub 2013 May 14.
    • Resolving the ductal carcinoma in situ treatment conundrum.
    • Berg CD.
    • J Natl Cancer Inst. 2013 May 15;105(10):680-1. doi: 10.1093/jnci/djt097. Epub 2013 May 2.
    • A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ.
    • Duggal S, Julian TB.
    • J Natl Cancer Inst. 2013 May 15;105(10):681-3. doi: 10.1093/jnci/djt098. Epub 2013 May 2.
    • A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
    • Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S.
    • J Natl Cancer Inst. 2013 May 15;105(10):701-10. doi: 10.1093/jnci/djt067. Epub 2013 May 2.
    • Breast Cancer Patients' Views on the Use of Genomic Testing to Guide Decisions about Their Postoperative Chemotherapy.
    • Seror V, Marino P, Bertucci F, Mancini J, Extra JM, Ferrero JM, Bachelot T, Viens P, Julian-Reynier C.
    • Public Health Genomics. [2013 May;]16(3):110-7. doi: 10.1159/000349920. Epub 2013 Apr 6.
    • DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
    • Kamieniak MM, Muñoz-Repeto I, Rico D, Osorio A, Urioste M, García-Donas J, Hernando S, Robles-Díaz L, Ramón Y Cajal T, Cazorla A, Sáez R, García-Bueno JM, Domingo S, Borrego S, Palacios J, van de Wiel MA, Ylstra B, Benítez J, García MJ.
    • Br J Cancer. 2013 Apr 30;108(8):1732-42. doi: 10.1038/bjc.2013.141. Epub 2013 Apr 4.
    • Genomic Subtypes in Choosing Adjuvant Therapy for Breast Cancer.
    • Amelia B. Zelnak, Ruth M. O'Regan.
    • Oncology 27(3). 2013 Mar 11.
    • The Evolving Role of Multi-Gene Tests in Breast Cancer Management.
    • Rachel C. Jankowitz, Adrian V. Lee.
    • Oncology 27(3). 2013 Mar 11.
    • Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.
    • Reed SD, Dinan MA, Schulman KA, Lyman GH.
    • Genet Med. 2013 Mar;15(3):203-11. doi: 10.1038/gim.2012.119. Epub 2012 Sep 13.
    • Interest and attitudes of patients, cancer physicians, medical students and cancer researchers towards a spectrum of genetic tests relevant to breast cancer patients.
    • Ngoi N, Lee SC, Hartman M, Khin LW, Wong A.
    • Breast. 2013 Feb;22(1):47-52. doi: 10.1016/j.breast.2012.04.003. Epub 2012 May 4.
    • Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    • Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX, Wan XP.
    • J Obstet Gynaecol Res. 2013 Feb;39(2):549-54. doi: 10.1111/j.1447-0756.2012.01979.x. Epub 2012 Sep 25.
    • Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
    • Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.
    • Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.
    • [Translational research and diagnostics for breast cancer].
    • Kreipe HH.
    • Pathologe. 2012 Nov;33 Suppl 2:282-90. doi: 10.1007/s00292-012-1645-1.
    • Review, [Article in German]
    • Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies.
    • Deverka PA, Schully SD, Ishibe N, Carlson JJ, Freedman A, Goddard KA, Khoury MJ, Ramsey SD.
    • Genet Med. 2012 Jul;14(7):656-62.
    • Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
    • Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC.
    • J Clin Oncol. 2012 Jun 20;30(18):2218-26. doi: 10.1200/JCO.2011.38.5740. Epub 2012 May 14.

    Editorial:

    Personalized medicine: what exactly is it and can we truly measure it?

    • The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay.
    • Laronga C, Harness JK, Dixon M, Borgen PI.
    • Am J Surg. 2012 Jun;203(6):751-8. doi: 10.1016/j.amjsurg.2011.07.024. Epub 2012 Apr 18.
    • Review

    Editorial:

    Commentary on "The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay".

    • A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.
    • Hallett RM, Pond G, Hassell JA.
    • BMC Med Genomics. 2012 May 11;5:16. doi: 10.1186/1755-8794-5-16.
    • Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    • Okada S, Tokunaga E, Kitao H, Akiyoshi S, Yamashita N, Saeki H, Oki E, Morita M, Kakeji Y, Maehara Y.
    • Ann Surg Oncol. 2012 May;19(5):1499-507. doi: 10.1245/s10434-011-2166-5. Epub 2011 Dec 17.
    • Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.
    • Kokate P, Sawaimoon S, Bhatia S, Mandava S.
    • Genet Test Mol Biomarkers. 2012 Apr;16(4):239-45. doi: 10.1089/gtmb.2011.0125. Epub 2011 Oct 24.
    • Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion.
    • Turna Ray.
    • Genome Web. 2012 Feb 8.

    Press: Not enough evidence for genetic breast cancer tests. (PHG Foundation)

    • 21-Gene recurrence scores: Racial differences in testing, scores, treatment, and outcome.
    • Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O'Regan RM.
    • Cancer. 2012 Feb 1;118(3):788-96. doi: 10.1002/cncr.26180. Epub 2011 Jun 30.
    • TLE3 Expression Is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma.
    • Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.
    • Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.
    • Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    • Hall PS, McCabe C, Stein RC, Cameron D.
    • J Natl Cancer Inst. 2012 Jan 4;104(1):56-66. doi: 10.1093/jnci/djr484. Epub 2011 Dec 2.
    • Integrating breast cancer genetics into clinical practice.
    • Mukherjee A, Rakha EA.
    • Womens Health (Lond Engl). 2012 Jan;8(1):99-112. doi: 10.2217/whe.11.81.
    • Review